Liminatus PharmaLIMN -5.02%13 3-Year RORE % is 65.18 as of Mar. 2026. GuruFocus rates LIMN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,288 Biotechnology companies, Liminatus Pharma ranks better than 92.86% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Liminatus Pharma's 3-Year RORE % for the quarter that ended in Mar. 2026 was 65.18%.
The industry rank for Liminatus Pharma's 3-Year RORE % or its related term are showing as below:
LIMN's 3-Year RORE % is ranked better than 92.86% of 1288
companies
in the Biotechnology industry
Industry Median: -11.54
vs LIMN: 65.18
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Liminatus Pharma 3-Year RORE % Related Terms
Liminatus Pharma 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Liminatus Pharma's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LIMN vs GNPX, PCSA, ELAB: 3-Year RORE % Comparison
For the Biotechnology subindustry, Liminatus Pharma's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liminatus Pharma 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Liminatus Pharma's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Liminatus Pharma's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Liminatus Pharma (LIMN) has a 3-Year RORE % of 65.18 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Liminatus Pharma and its competitors. According to the industry distribution chart, Liminatus Pharma ranks #92 out of 1288 companies in the Biotechnology industry, placing it in the top 7.1%.
Is Liminatus Pharma's 3-Year RORE % too high?
Liminatus Pharma's current 3-Year RORE % is 65.18. Based on the distribution chart, Liminatus Pharma ranks #92 out of 1288 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Liminatus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Liminatus Pharma's 3-Year RORE % compare to GNPX and PCSA?
According to the Biotechnology industry distribution chart, Liminatus Pharma ranks #92 out of 1288 companies for 3-Year RORE %. This places Liminatus Pharma in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Liminatus Pharma and its competitors. Liminatus Pharma's current 3-Year RORE % is 65.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current 3-Year RORE % of 65.18. The current 3-Year RORE % is 65.18. Liminatus Pharma's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current 3-Year RORE % is 65.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
13GF Score
Get the complete analysis for LIMN
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIMN has been successfully added to your 
